Source: Archives of Ophthalmology
Area: News
The 2-year outcomes of the BOLT study, a prospective RCT evaluating intravitreal bevacizumab* and modified Early Treatment Diabetic Retinopathy Study (ETDRS) macular laser therapy (MLT) in patients with persistent clinically significant macular oedema (CSMO) have been published.
The study involved 80 patients with center-involving CSMO and visual acuity of 20/40 to 20/320 who were randomised to receive either bevacizumab or MLT. The primary outcome was the difference in ETDRS best-corrected visual acuity (BCVA) between arms. Secondary outcomes were mean change in BCVA, proportion gaining at least 15 and at least 10 ETDRS letters, losing fewer than 15 and at least 30 letters, change in central macular thickness, ETDRS retinopathy severity, and safety outcomes.
The following findings were reported:
. At 2 years, mean ETDRS BCVA was 64.4 (ETDRS equivalent Snellen fraction: 20/50) in the bevacizumab arm and 54.8 (20/80) in the MLT arm ...
Uncategorized